Research programme: pDNA cancer vaccines - Genetic Immunity/Pharmadis
Latest Information Update: 28 Feb 2023
At a glance
- Originator Genetic Immunity
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Cancer in USA (Transdermal, Patch)
- 29 Jan 2019 Genetic Immunity expands agreement with Pharmadis and grants 20 pDNA cancer vaccine licenses for Russia and Commonwealth of Independent States
- 29 Jan 2019 Early research in Cancer in USA (Transdermal) prior to January 2019